METHOD FOR PREDICTING RESPONSE TO CANCER IMMUNOTHERAPY BY USING DNA METHYLATION ABERRATION IN LINE-1

• Main Authors: CHO, Dae Yeon, NOH, Seung Jae, KIM, Kyeong Hui, SHIN, In Kyung, CHOI, Jung Kyoon
• Format: Patent
• Language: English; French; Korean
• Published: 06.04.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present disclosure relates to a method for providing information for predicting a response to cancer therapy, comprising the step of obtaining information on a DNA methylation level of a long interspersed nuclear element-1 (LINE-1) subfamily from an isolated sample of a cancer patient, wherein the LINE-1 subfamily is at least one selected from the group consisting of L1PA12_5end, L1HS_5end, L1PA10_3end, L1P2_5end, L1PA11_3end, L1P2_5end, L1PA13_3end, L1PA11_3end, and L1P1_orf2. La présente divulgation concerne un procédé pour fournir des informations pour prévoir une réponse à une thérapie anticancéreuse, comprenant l'étape consistant à obtenir des informations sur un niveau de méthylation d'ADN d'une sous-famille d'élément nucléaire intercalé long-1 (LINE-1) à partir d'un échantillon isolé d'un patient cancéreux, la sous-famille LINE-1 étant au moins un élément choisi dans le groupe constitué par L1PA12_5end, L1HS_5end, L1PA10_3end, L1P2_5end, L1PA11_3end, L1P2_5end, L1PA13_3end, L1PA11_3end et L1P1_orf2. 본 개시는 암 환자의 분리된 시료로부터 LINE-1(Long Interspersed Nuclear Element-1) 서브 패밀리의 DNA 메틸화 수준에 관한 정보를 획득하는 단계를 포함하고, 상기 LINE-1 서브 패밀리는, L1PA12_5end, L1HS_5end, L1PA10_3end, L1P2_5end, L1PA11_3end, L1P2_5end, L1PA13_3end, L1PA11_3end 및 L1P1_orf2로 이루어진 군으로부터 선택되는 1종 이상인, 암 치료 반응성 예측을 위한 정보제공 방법에 관한 것이다.